Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
Thousands of somatic mutations accrue in most human cancers, and their causes are largely unknown. We recently showed that the DNA cytidine deaminase APOBEC3B accounts for up to half of the mutational load in breast carcinomas expressing this enzyme. Here we address whether APOBEC3B is broadly responsible for mutagenesis in multiple tumor types. We analyzed gene expression data and mutation patterns, distributions and loads for 19 different cancer types, with over 4,800 exomes and 1,000,000 somatic mutations. Notably, APOBEC3B is upregulated, and its preferred target sequence is frequently mutated and clustered in at least six distinct cancers: bladder, cervix, lung (adenocarcinoma and squamous cell carcinoma), head and neck, and breast. Interpreting these findings in the light of previous genetic, cellular and biochemical studies, the most parsimonious conclusion from these global analyses is that APOBEC3B-catalyzed genomic uracil lesions are responsible for a large proportion of both dispersed and clustered mutations in multiple distinct cancers.
在大多数人类癌症中,会积累数千种体细胞突变,但其原因在很大程度上尚不清楚。我们最近表明,在表达这种酶的乳腺癌中,DNA 胞嘧啶脱氨酶 APOBEC3B 占突变负荷的一半之多。在这里,我们探讨 APOBEC3B 是否广泛负责多种肿瘤类型的致突变作用。我们分析了 19 种不同癌症类型的基因表达数据和突变模式、分布和负荷,其中包括超过 4800 个外显子和 100 万个体细胞突变。值得注意的是,APOBEC3B 上调,其首选靶序列在至少六种不同的癌症中经常发生突变和聚集:膀胱癌、宫颈癌、肺癌(腺癌和鳞状细胞癌)、头颈部癌和乳腺癌。根据先前的遗传、细胞和生化研究的结果,从这些全球分析中得出的最合理的结论是,APOBEC3B 催化的基因组尿嘧啶损伤负责多种不同癌症中离散和聚集突变的很大一部分。